Literature DB >> 24315042

Influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies.

Michael Haake1, Andreas Palzer2, Beate Rist2, Christiane Weissenbacher-Lang3, Vicky Fachinger4, Alex Eggen5, Mathias Ritzmann6, Matthias Eddicks2.   

Abstract

Two field studies were conducted to investigate the influence of age on the efficacy of vaccination against Porcine Circovirus Diseases (PCVD) in animals with high levels of maternally derived antibodies (MDA). A total of 416 piglets (Study 1) and 600 piglets (Study 2) were randomly allocated to one of three groups. Two groups in each study received a single dose of a PCV2 subunit vaccine, one group at 1 week old and the other at 3 weeks of age. The third group was left untreated. Animals vaccinated at 3 weeks of age showed a significantly higher average daily weight gain and significantly reduced viraemia following PCV2 infection than the respective control groups. This difference was not observed in pigs vaccinated at 1 week of age. Furthermore, only animals vaccinated at 3 weeks of age showed an increased serological response and a higher frequency of IgM-positive animals compared with controls. The data indicated that PCV2 vaccination in the presence of high MDA levels is efficacious when used in 3-week old but not in 1-week old pigs. As the range of MDA titres of pigs vaccinated at both 1 and 3 weeks of age were comparable, the data suggest that PCV2 vaccine efficacy was independent of the level of MDA. It appears that other age-related factors affecting the active and passive transfer of immunity may perhaps have interfered with the efficacy of the vaccine in 1-week old piglets. These findings have implications for future PCV2 vaccine testing and administration strategies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal health; MDA; Neonate; PCV2; Swine; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 24315042     DOI: 10.1016/j.vetmic.2013.11.012

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  14 in total

1.  Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.

Authors:  Darrell R Kapczynski; Terrence M Tumpey; Rachmat Hidajat; Aniko Zsak; Klaudia Chrzastek; Irina Tretyakova; Peter Pushko
Journal:  Vaccine       Date:  2016-02-08       Impact factor: 3.641

2.  Efficacy of a novel intradermal Lawsonia intracellularis vaccine in pigs against experimental infection and under field conditions.

Authors:  A A C Jacobs; F Harks; R Pauwels; Q Cao; H Holtslag; S Pel; R P A M Segers
Journal:  Porcine Health Manag       Date:  2020-10-01

3.  Impact of maternally derived immunity on piglets' immune response and protection against porcine circovirus type 2 (PCV2) after vaccination against PCV2 at different age.

Authors:  Paolo Martelli; Roberta Saleri; Giulia Ferrarini; Elena De Angelis; Valeria Cavalli; Michele Benetti; Luca Ferrari; Elena Canelli; Paolo Bonilauri; Elena Arioli; Antonio Caleffi; Heiko Nathues; Paolo Borghetti
Journal:  BMC Vet Res       Date:  2016-05-11       Impact factor: 2.741

4.  Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages.

Authors:  Salvador Oliver-Ferrando; Joaquim Segalés; Sergio López-Soria; Antonio Callén; Olivier Merdy; François Joisel; Marina Sibila
Journal:  Vet Res       Date:  2016-12-03       Impact factor: 3.683

5.  A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs.

Authors:  Panagiotis D Tassis; Ioannis Tsakmakidis; Vassileios G Papatsiros; Dimitrios Koulialis; Tom Nell; Georgia Brellou; Eleni D Tzika
Journal:  BMC Vet Res       Date:  2017-04-07       Impact factor: 2.741

6.  Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm.

Authors:  Eleni D Tzika; Panagiotis D Tassis; Dimitrios Koulialis; Vassileios G Papatsiros; Tom Nell; Georgia Brellou; Ioannis Tsakmakidis
Journal:  Porcine Health Manag       Date:  2015-11-01

7.  Cross-Sectional Study on the Sero- and Viral Dynamics of Porcine Circovirus Type 2 in the Field.

Authors:  Chao-Nan Lin; Ni-Jyun Ke; Ming-Tang Chiou
Journal:  Vaccines (Basel)       Date:  2020-06-26

8.  Effect of Porcine circovirus 2 (PCV-2) maternally derived antibodies on performance and PCV-2 viremia in vaccinated piglets under field conditions.

Authors:  S Figueras-Gourgues; L Fraile; J Segalés; I Hernández-Caravaca; R López-Úbeda; F A García-Vázquez; O Gomez-Duran; B Grosse-Liesner
Journal:  Porcine Health Manag       Date:  2019-09-05

9.  Exploratory field study on the effects of porcine circovirus 2 (PCV-2) sow vaccination at different physiological stages mimicking blanket vaccination.

Authors:  Patricia Pleguezuelos; Marina Sibila; Raúl Cuadrado; Rosa López-Jiménez; Diego Pérez; Eva Huerta; Anna M Llorens; José Ignacio Núñez; Joaquim Segalés; Sergio López-Soria
Journal:  Porcine Health Manag       Date:  2021-04-26

10.  Efficacy of Two Commercial Ready-To-Use PCV2 and Mycoplasma hyopneumoniae Vaccines under Field Conditions.

Authors:  Gonzalo López-Lorenzo; Alberto Prieto; Cynthia López-Novo; Pablo Díaz; Ceferino Manuel López; Patrocinio Morrondo; Gonzalo Fernández; José Manuel Díaz-Cao
Journal:  Animals (Basel)       Date:  2021-05-26       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.